CATALOGO DEI PRODOTTI DELLA RICERCA

BONIFACIO, Massimiliano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 8.353
NA - Nord America 7.612
AS - Asia 6.158
SA - Sud America 982
AF - Africa 118
OC - Oceania 34
Continente sconosciuto - Info sul continente non disponibili 7
AN - Antartide 1
Totale 23.265
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.458
RU - Federazione Russa 3.558
SG - Singapore 2.303
CN - Cina 2.142
GB - Regno Unito 1.516
BR - Brasile 818
IT - Italia 680
HK - Hong Kong 635
DE - Germania 516
SE - Svezia 489
FR - Francia 444
VN - Vietnam 442
IE - Irlanda 411
FI - Finlandia 292
KR - Corea 147
IN - India 106
UA - Ucraina 101
CA - Canada 81
NL - Olanda 76
ID - Indonesia 67
AR - Argentina 64
PL - Polonia 64
JP - Giappone 54
MX - Messico 49
TR - Turchia 48
BE - Belgio 40
BD - Bangladesh 38
AT - Austria 34
ES - Italia 32
AU - Australia 29
EC - Ecuador 24
IR - Iran 24
IQ - Iraq 23
TG - Togo 22
ZA - Sudafrica 22
VE - Venezuela 19
CL - Cile 16
CO - Colombia 16
MA - Marocco 14
RO - Romania 14
AZ - Azerbaigian 12
BJ - Benin 12
UZ - Uzbekistan 12
PK - Pakistan 11
CZ - Repubblica Ceca 10
DZ - Algeria 10
GR - Grecia 10
CH - Svizzera 9
LT - Lituania 9
NP - Nepal 9
PE - Perù 9
AE - Emirati Arabi Uniti 8
JO - Giordania 8
KZ - Kazakistan 8
PY - Paraguay 8
TN - Tunisia 8
CG - Congo 7
DK - Danimarca 7
NO - Norvegia 7
IL - Israele 6
CR - Costa Rica 5
JM - Giamaica 5
KG - Kirghizistan 5
PT - Portogallo 5
TW - Taiwan 5
BO - Bolivia 4
EU - Europa 4
LV - Lettonia 4
MY - Malesia 4
NG - Nigeria 4
NZ - Nuova Zelanda 4
SY - Repubblica araba siriana 4
TH - Thailandia 4
UY - Uruguay 4
AL - Albania 3
AM - Armenia 3
BH - Bahrain 3
BY - Bielorussia 3
EG - Egitto 3
GE - Georgia 3
HU - Ungheria 3
KE - Kenya 3
LA - Repubblica Popolare Democratica del Laos 3
LK - Sri Lanka 3
PA - Panama 3
PH - Filippine 3
QA - Qatar 3
RS - Serbia 3
SA - Arabia Saudita 3
SN - Senegal 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BG - Bulgaria 2
DM - Dominica 2
ET - Etiopia 2
HN - Honduras 2
KH - Cambogia 2
LY - Libia 2
MK - Macedonia 2
NI - Nicaragua 2
SI - Slovenia 2
Totale 23.237
Salva come PNG Salva come JPEG
Città #
Southend 1.303
Moscow 1.159
Singapore 1.074
Chandler 968
Dallas 931
Ashburn 632
Hong Kong 630
Woodbridge 505
Beijing 493
Dublin 409
Ann Arbor 329
Jacksonville 267
Houston 263
The Dalles 253
Wilmington 194
Verona 189
New York 185
Lawrence 172
Princeton 172
Los Angeles 157
Ho Chi Minh City 135
Jinan 133
Nanjing 123
Shenyang 123
Munich 97
Hanoi 90
Redmond 88
Buffalo 80
Redondo Beach 78
Sindelfingen 78
Columbus 77
Hebei 76
Helsinki 73
São Paulo 72
Tianjin 68
Santa Clara 55
Zhengzhou 54
Warsaw 53
Tokyo 49
Changsha 48
Milan 48
Falls Church 46
Nanchang 46
Taizhou 45
Fuzhou 44
Jakarta 44
Ningbo 44
Bologna 43
Redwood City 43
Guangzhou 42
Dong Ket 40
Brussels 39
Chicago 39
Hangzhou 39
Nuremberg 38
Haikou 37
Turku 37
Seoul 36
Seattle 35
London 33
Montreal 30
Norwalk 30
San Francisco 30
Rio de Janeiro 28
Atlanta 27
Chennai 27
Jiaxing 27
Kent 27
Belo Horizonte 26
Denver 26
Orem 25
Taiyuan 25
Council Bluffs 24
Rome 24
Poplar 23
Boardman 22
Boston 22
Falkenstein 22
Lomé 22
Stockholm 22
Groningen 21
Frankfurt am Main 19
Mexico City 19
Amsterdam 18
Johannesburg 18
San Jose 18
Phoenix 17
Dearborn 16
Provo 16
Shanghai 16
Vienna 16
Brasília 15
Düsseldorf 15
Lanzhou 15
Toronto 15
Chengdu 13
Lancaster 13
Lappeenranta 13
San Giovanni Lupatoto 13
Ankara 12
Totale 13.580
Salva come PNG Salva come JPEG
Nome #
Epidemiology of mastocytosis in adults based on a multidisciplinary diagnostic approach. 302
A study of the crosstalk between CD30 and CXCR4 224
Notch singalling inhibition as a multi-target therapy to overcome bone marrow microenvironment-mediated drug resistance in AML 223
CAL2 Monoclonal Antibody Is a Rapid and Sensitive Assay for the Detection of Calreticulin Mutations in Essential Thrombocythemia and May Provide Prognostic Informations 223
CD66b-CD64dimCD115- cells in the human bone marrow represent neutrophil-committed progenitors 221
Role of GSK-3 signalling in non-promyelocitic acute myeloid leukemia (AML) cell response to chemotherapy 220
Notch signalling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemia 213
Role of Wnt/β-Catenin Signalling in Acute Myeloid Leukemia (AML) Cell Response to Chemotherapy 213
A preliminary experience with the HyperCHiDAM Verona intensive chemotherapy regimen in heavily pretreated refractory Hodgkin's lymphoma 208
Inhibition of GSK-3 Signalling Enhances Sensitivity of Non-Promyelocitic Acute Myeloid Leukemia (AML) Cell to Chemotherapy 204
BCR-ABL fusion transcript b2a2 is associated with a higher risk of non-optimal early response in CP-CML patients treated with standard dose imatinib: a study from Gruppo Triveneto LMC. 201
Absence of TCL1A expression is a useful diagnostic feature in splenic marginal zone lymphoma. 200
Clonal mast cell disorders limited to bone marrow: not a negligible disease. 200
Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis 196
CXCL12 and [N33A]CXCL12 in 5637 and HeLa Cells: Regulating HER1 Phosphorylation via Calmodulin/Calcineurin 194
Rational of targeting WNT/beta-catenin signaling in acute myeloid leukemia (AML) 190
Inhibition of Notch signalling overcomes bone marrow stromal-mediated anti-apoptotic and chemoresistance effects in AML. 189
ALK-positive anaplastic large cell lymphoma with PAX-5 expression: report of a case 188
Anaphylactic Reactions After Discontinuation of Hymenoptera Venom Immunotherapy: A Clonal Mast Cell Disorder Should Be Suspected 188
Autoimmune complications are frequent in splenic and nodal marginal zone lymphomas 182
Predictive factors of stable deep molecular response in chronic myeloid leukemia patients treated with imatinib standard dose: a study from the Gruppo Triveneto LMC. 181
Longitudinal Evaluation of Bone Mineral Density and Bone Metabolism Markers in Patients with Indolent Systemic Mastocytosis Without Osteoporosis 180
Value of flow cytometry in the diagnosis of indolent systemic mastocytosis. 178
A simple score predicts clonal mast cell disorders in patients with systemic reactions to Hymenoptera venom without skin lesions 178
Somatic D816V KIT mutation in a case of adult-onset familial mastocytosis. 175
CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia and may provide prognostic informations 175
A Survey on Clinical and Biological Characteristic and Therapy Management of an Italian Series of 455 Adult Patients with Systemic Mastocytosis on Behalf of Italian Registry of Mastocytosis 172
Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories 172
Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels 171
Predictors of stable deep molecular response in chronic phase chronic myeloid leukemia patients treated with dasatinib or nilotinib after imatinib failure 168
Predictors for response to ruxolitinib in real-life: an observational independent study on 266 patients with myelofibrosis 168
The Sesquiterpene Oil {alpha}-Bisabolol Induces Apoptosis of B-Chronic Lymphocytic Leukemia Primary Cells 167
α-bisabolol is an effective proapoptotic agent against BCR-ABL+ cells in synergism with Imatinib and Nilotinib 166
Regulative Loop between β-catenin and Protein Tyrosine Receptor Type γ in Chronic Myeloid Leukemia 165
Small Molecule Inhibitors of Microenvironmental Wnt/β-Catenin Signaling Enhance the Chemosensitivity of Acute Myeloid Leukemia 163
A Multidisciplinary Diagnostic Approach Reveals a Higher Prevalence of Indolent Systemic Mastocytosis: 15-Years’ Experience of the GISM Network 163
The impact of sensitive KIT D816V detection on recognition of Indolent Systemic Mastocytosis 162
CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia patients 162
Inhibition of Notch signaling enhances chemosensitivity in B cell precursor acute lymphoblastic leukemia 161
BLAST: A Confirmatory, Single-Arm, Phase 2 Study of Blinatumomab, a Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Patients with Minimal Residual Disease B-Precursor Acute Lymphoblastic Leukemia (ALL) 159
Back to life – Living, treating, managing myelofibrosis: the burden of illness for patients and their families 158
Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis 158
Improved detection of the C-KIT D816V mutation using allele-specific arms real time PCR assay allows a finer recognition of patients with indolent systemic mastocytosis. 157
Plasmacytoid dendritic cell leukemia: a rapidly evolving disease presenting with skin lesions sensitive to radiotherapy plus hyperthermia. 156
The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population 155
Therapeutic targeting of Lyn kinase to treat chorea-acanthocytosis 154
Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy 152
Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response 151
Notch Signaling Molecules as Prognostic Biomarkers for Acute Myeloid Leukemia 150
Comparison of dasatinib and nilotinib as second-line therapy after imatinib failure in chronic phase chronic myeloid leukemia patients. 149
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 149
Pro-apoptotic activity of α-bisabolol in preclinical models of primary human acute leukemia cells 148
Bone Disease in Mastocytosis 148
Molecular “warning” CML patients: a retrospective study of Gruppo Triveneto LMC. 146
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis 146
Multiple large osteolytic lesions in a patient with systemic mastocytosis: a challenging diagnosis 145
Uncovering two neutrophil-committed progenitors that immediately precede promyelocytes during human neutropoiesis 143
Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis 141
Short-term, intensive chemotherapy regimen is equally effective in Burkitt lymphoma (BL) and in the novel WHO 2008 entity “B-cell lymphoma intermediate between DLBCL and BL". 140
Mitochondrial-Mediated Apoptosis by the Sesquiterpene Oil {alpha}-Bisabolol and Its Synergism with Imatinib and Nilotinib In BCR-ABL+ Cells. 139
Unexpected subacute leucoencephalopathy following intrathecal methotrexate and cytarabine administration in a patient homozygous for MTHFR 677C→T polymorphism. 139
Sesquiterpene α-bisabolol, which binds to Bid in lipid rafts, induces apoptosis in BCR/ABL+ cell lines through membrane depolarization. 138
Systemic mastocytosis: a muldisciplinary approach (Review) [Lamastocitosi sistemica: Un approccio multidiscliplinare] 138
The impact of a 7-day prednisone (PDN) pretreatment in adult (less than 60y) acute lymphoblastic leukemia (ALL) therapy: results of LAL2000 vs LAL0496. 138
Ultra-deep sequencing (UDS) allows more sensitive detection of the D816V and other KIT gene mutations in systemic mastocytosis 138
Characterization of a new B-ALL cell line with constitutional defect of the Notch signaling pathway 138
Regulative loop between beta-catenin and protein tyrosine phosphatase receptor type gamma (PTPRG) in chronic myeloid leukemia 137
TP53 mutations in adult acute lymphoblastic leukemia (ALL) are relatively frequent in molecularly negative case of both B- and T-lineage and correlate with poor response to induction therapy 134
A critical comparison of Sokal, Euro, and Eutos risk scores in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. 134
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎ 134
Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements 134
A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements 133
Real-life comparison of dasatinib and nilotinib as second-line therapy after imatinib failure for chronic phase CML 133
Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis 132
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study 132
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms 132
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients 131
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 131
Hyperchidam Verona897 Regimen Is Effective in Treatment of Advanced Peripheral T Cell Lymphoma (PTCL): The GITIL Experience in 33 Cases 130
Serum tryptase levels differently change over time in indolent systemic mastocytosis with or without skin lesions. 130
Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients 129
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients 128
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study 128
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 126
EUTOS Score Identifies Cases with Poor Outcome in Patients with Early Chronic Phase Chronic Myeloid Leukemia, Though Not Predictive for Optimal Response to Imatinib 125
Modified HyperCVAD and rituximab for the treatment of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. 123
High levels of tumor load reduction after intensive chemotherapy favorably affect the prognosis of BCR/ABL+ ALL adult patients receiving Imatinib Mesylate alone as a post-consolidation treatment according to the Italian GIMEMA LAL 0201/A protocol 121
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 121
Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged $greater$65~years resistant/intolerant to previous tyrosine-kinase inhibitors 121
High incidence of autoimmune complications in 82 patients with non-MALT marginal zone lymphomas. 120
BCR-ABL mutations in chronic myeloid leukemia (CML) patients (pts) with failure and warning to first- and second-lline tyrosine kinase inhibitor (TKI) therapy: what is the advantage of Next-Generation Sequencing (NGS) over conventional sequencing? 120
PBX/E2A transcript positive B-lymphoblastic leukemia (B-ALL) presenting with bilateral renal and myocardial involvement: a case report. 119
Systemic mastocytosis associated with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Report of three cases 119
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study 118
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 116
Hymenoptera Anaphylaxis and C-kit Mutations: An Unexpected Association 115
Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification 115
Skeletal implications of isolated bone marrow mastocytosis (reply): Indolent systemic mastocytosis without skin involvement vs. isolated bone marrow mastocytosis (reply) 114
Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia 114
In Chronic Myeloid Leukemia Patients on 2nd-Line Tyrosine Kinase Inhibitor Therapy, Deep Sequencing at the Time of Warning May Allow Sensitive Detection of Emerging BCR-ABL1 Mutants 113
Totale 15.641
Salva come PNG Salva come JPEG
Categoria #
all - tutte 83.518
article - articoli 56.148
book - libri 0
conference - conferenze 26.955
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 415
Totale 167.036
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021478 0 0 0 0 0 108 22 22 50 20 162 94
2021/20221.381 106 374 36 141 109 56 24 73 72 40 78 272
2022/20232.692 190 264 263 470 208 704 33 152 297 24 46 41
2023/20241.596 73 128 90 158 175 197 63 109 27 86 379 111
2024/20254.293 188 241 214 703 183 141 210 238 629 318 425 803
2025/20268.364 881 747 903 2.060 3.080 693 0 0 0 0 0 0
Totale 23.563